making it one of the most expensive therapies in the U.S. Mizuho said the selling of the stock was likely an overreaction, noting that this is the first case of acute liver failure among patients ...
Gov. Tim Walz (D-MN) is living a “sad existence” for cheering the demise of Elon Musk ‘s car company, the White House said Wednesday.
Sarepta Therapeutics Inc.'s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug ...
What's at stake with SVB's failure. How SVB failed. Implications and questions. Bottom line for investors. Investors in SIVB stock will suffer a catastrophic and total loss. But beyond individual ...
Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.
New data show that AMC's failure-to-deliver rates have peaked over the past two months. With this key indicator sitting at an all-time high, here’s what investors should know. Rocketing trade ...
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) stock is sliding. The company shared an update on Elevidys (delandistrogene moxeparvovec-rokl), the only approved gene therapy in patients with Duchenne ...
2don MSN
The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.
Sarepta Therapeutics Inc.’s stock tumbled 23% on Tuesday after the ... Duchenne muscular dystrophy has died of acute liver failure. While liver failure is a known possible side effect of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results